IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Ranbaxy Launches Generic Version of Lipitor

December 6, 2011 | Deepti Ramesh

The U.S. Food and Drug Administration (FDA) has approved the first generic version of Pfizer’s cholesterol-lowering drug Lipitor - atorvastatin calcium tablets. Ranbaxy Pharmaceuticals (Jacksonville, FL) USA, a subsidiary of Ranbaxy Laboratories (Gurgaon, India) received final approval from the FDA to manufacture and market atorvastatin and has launched the product in the U.S. market on December 1. Lipitor, the top-selling drug, generates annual sales of about $7.89 billion in the U.S., Ranbaxy says. Ranbaxy has gained approval to make generic atorvastatin...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa